Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of COR388 HCl in Subjects With Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of COR388 HCl in Subjects With Alzheimer's Disease

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs COR-388 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Cortexyme
  • Most Recent Events

    • 27 Sep 2018 According to a Cortexyme media release, the company has announced the formation of a new Clinical Advisory Board (CAB) in preparation for starting Phase II clinical development in Alzheimer's disease next year.
    • 07 Jun 2018 New trial record
    • 31 May 2018 According to a Cortexyme media release, the company is planning to initiate this study next year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top